Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco Animal Health Inc President, CEO and Director Jeffrey N. Simmons reported a tax-withholding disposition of 37,898 shares of common stock on March 3, 2026. The disposition, coded as a payment of tax liability, was priced at $24.88 per share.
After this transaction, Simmons directly held 2,051,898 shares of Elanco common stock. A separate line shows an indirect holding of 167,000 shares held by a revocable trust, reported as indirect beneficial ownership.
Elanco Animal Health Inc officer Timothy J. Bettington reported a tax-withholding disposition of 4,695 shares of common stock on March 3, 2026. The shares were transferred at $24.88 per share to cover tax obligations, rather than sold in an open-market transaction. After this transaction, Bettington directly held 143,261 shares of Elanco common stock.
Elanco Animal Health officer Cabral Ramiro Martin reported a tax-withholding disposition of 6,492 shares of common stock at $24.88 per share on March 3, 2026. After this non-market transaction, he directly owned 283,874 common shares.
Elanco Animal Health Inc officer Jose Manuel Correia de Simas reported a tax-related share disposition. On March 3, 2026, he transferred 3,371 shares of common stock at $24.88 per share to cover tax withholding, and held 101,017 shares directly afterward.
Elanco Animal Health Inc executive Ellen de Brabander reported a tax-related stock transaction. On this Form 4, she disposed of 8,262 shares of Common Stock on March 3, 2026 through a tax-withholding disposition at a price of $24.88 per share, leaving her with 260,124 directly owned shares.
Elanco Animal Health Inc executive David S. Kinard reported a Form 4 transaction involving company common stock. On March 3, 2026, Kinard had a tax-related disposition of 3,433 shares of common stock at a reported price of $24.88 per share. This transaction is coded as a tax-withholding disposition, meaning shares were surrendered to cover tax obligations rather than being sold on the open market. After this transaction, Kinard directly held 214,264 shares of Elanco Animal Health Inc common stock.
Elanco Animal Health Inc executive Grace McArdle, EVP, Manufacturing and Quality, reported a tax-related share disposition. On March 3, 2026, she disposed of 4,322 shares of Elanco common stock at $24.88 per share in a transaction classified as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in an open-market trade. Following this transaction, she directly held 103,705 shares of Elanco common stock.
Elanco Animal Health Inc chief accounting officer James M. Meer reported a tax-related share disposition. On the reported date, he transferred 1,389 shares of Common Stock at $24.88 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 66,732 Common Stock shares.
Elanco Animal Health chief accounting officer James M. Meer reported equity compensation and related tax withholding transactions in company common stock. He received grants classified as restricted stock units covering 9,596 shares and 5,209 shares, both at a stated price of $0.00 per share. A separate transaction disposed of 4,787 shares at $26.40 per share to satisfy tax liability by delivering shares. The restricted stock units vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Rajeev A. Modi reported multiple equity awards and related tax withholding transactions. On March 1, 2026, he received 29,025 employee stock options and 2,532 deferred stock units at no cost. He was also granted 41,690 shares of common stock and an additional 14,205 restricted stock units, all as equity awards.
The stock options and restricted stock units each vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The deferred stock units vest on December 31, 2027 and settle in stock or cash upon termination of employment under the Executive Deferral and Stock Match Plan. To cover tax obligations, 19,375 common shares were disposed of at $26.40 per share through share delivery. Following these transactions, Modi directly owned 160,293 shares of Elanco common stock as of March 1, 2026.